spacer
home > ebr > spring 2004 > patently better - the rights and wrongs of patent protection drug discovery technology
PUBLICATIONS
European Biopharmaceutical Review

Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology

Whether to secure development funding, protect product licence fees or simply to stop third parties profiting from the fruits of their research, the patent is an essential business tool for firms in the biopharmaceutical field. This article looks at the essential role that patents play, and explores some important recent changes affecting the availability of patent protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gareth Williams is a Patent Attorney and European Trade Mark Attorney at Marks and Clerk. Gareth obtained an honours degree in Biological Sciences from Oxford University, where he remained to complete a doctorate in Molecular Biology and Genetics researching the Y chromosome, funded as part of the Human Genome Project. He entered the patent profession in 1998 and is a qualified UK and European Patent Attorney. He has acted for clients in a variety of fields, but specialises particularly in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy.

spacer
Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Rapid Micro Biosystems Announces New Corporate Headquarters

Rapid Micro Biosystems, a leading provider of automated, nondestructive, rapid microbial detection, today announced its recent move to a new corporate headquarters in Lowell, Massachusetts.
More info >>

White Papers

RUNNING SMARTER TRIALS WITH DATA-DRIVEN MONITORING

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm. Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little. Now, after several years of industry discussion and recent industry collaboration1, there’s solidifying consensus that adoption of data-driven monitoring can substantially improve study quality, safety, and also reduce monitoring costs, which today account for 15-30% of total study costs. Data-driven monitoring represents a major departure from traditional monitoring in which clinical research associates (CRA) typically visit sites on a fixed schedule. Instead, data-driven monitoring leverages eClinical technology (EDC, CTMS, RTSM) to turn monitoring into a flexible, responsive, team-based activity.
More info >>

 
Industry Events

Clinical Trials in CNS

11-12 November 2014, Marriott Regents Park Hotel, London, UK

SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement